Dr. Lincoln Nadauld is a physician scientist and medical oncologist at Intermountain Health, where he leverages electronic and biological patient data to drive discoveries in diagnostics, therapeutics, and care models.
Prior to this, he founded and led the Intermountain Precision Genomics program. He also served as Intermountain Healthcare’s Chief of Precision Health and Academics, spearheading the clinical integration of precision health across their extensive network. Dr. Nadauld conceived and directed the Heredigene Population Study, an initiative focused on whole genome sequencing of 500,000 Intermountain participants.
His contributions have been recognized with the Utah Governor’s 32nd Annual Science Medal for Industry and the 2020 C2 Catalyst for Precision Medicine award. He was also named a “Top 50 Healthcare Innovator” by Modern Healthcare and has published over 50 peer-reviewed articles. Additionally, he has served as an editor for the Journal of Clinical Oncology-Precision Oncology.